Immunotherapy and vaccine specialist Circassia says its new license agreement with NanoPass Technologies will help its range of allergy products to thrive on the market.
Vical has published a review of Vaxfectin data showing the adjuvant boosts the immune response of DNA-based vaccines against cancer and a range of pathogens.
Reengineering erythropoietin (EPO) as an immunoglobulin G (IgG) fusion protein enables penetration of the blood-brain barrier (BBB) in mice, according to researchers.
SAFC and Novozymes Biopharma have agreed to extend their partnership by ten years for the exclusive distribution of LONG R3 growth factor, used for industrial cell culture applications.
Pfenex has won a US federal contract to use its expression technology for the rapid, cost-effective production of “unprecedented” amounts of anthrax vaccine.
Tanabe Research Labs (TRL) has revealed details of its new San Diego facility in which the revised layout of the site allows a fresh focus on antibody and biological approaches to autoimmune diseases such as diabetes and rheumatoid arthritis.
PPD has added capabilities at the facility acquired from Merck & Co and improved integration of other sites to create its Vaccines & Biologics Center of Excellence, a single provider of multiple laboratory services.
InNexus Biotechnology believes 2010 is the year for biotechs to differentiate and has begun this process by using its Transmab delivery technology in a product for treating psoriasis.
MedImmune has recalled unused doses of its intranasal H1N1 vaccine FluMist in the US after checks revealed that some had fallen below the minimum potency threshold in the two months since they were shipped.
Intercell’s needle-free patch delivery technology has the potential to change the way vaccines are delivered, according to Jean Stephenne, president of GSK Biologicals.
Lonza has bolstered its protein design capabilities by acquiring Algonomics, a CRO with technologies which predict immunogenicity to improve development of protein therapeutics and vaccines.
French biopharmaceutical group LFB has contracted Lonza’s biopharmaceuticals division to make trial supplies of its candidated monoclonal anti-RhD antibody.
FIT Biotech has entered into a partnership that will see its GTU MultiHIV DNA plasmid developed using ImmunoVaccine Technologies’ DepoVax delivery tool, which uses liposomes to encapsulate a target antigen and adjuvant.
OutsourcingPharna.com presents a round-up of recent contracts awarded to contract development and manufacturing services companies – and finds a lot of activity in the biomanufacturing sector.
US-based BioReliance has won the contract to supply bulk adenovirus for several live oral vaccines being produced by Barr Pharmaceutical’s Duramed subsidiary.
UK company ProImmune has launched a suite of services to help drugmakers determine at an early stage whether a biologic drug will elicit an immune response in humans.
New Zealand has approved clinical trials of Living Cell Technologies (LCT) type 1 diabetes treatment, which uses porcine cells encapsulated in a seaweed based gel.
Bio-Rad has published new results showing how its ProteOn XPR36 protein interaction array system can dramatically speed up monoclonal antibody (mAb) screening.
US-based DSM Biologics and MorphoSys are teaming up to manufacture the MOR202 antibody, which has shown considerable promise as a treatment for multiple myeloma (MM).
Bioprocessing specialist Sartorius Stedim Biotech’s (SSB) net profit for the first half of 2008 rose by 3.5 per cent in comparison with last year, although the company continues to face difficulties in North America.
In an ironic twist, researchers have shown that the tobacco plant, the cause of millions of cases of cancer, can be harnessed to produce personalised cancer vaccines.
Modigene says that data from a trial of a Schering-Plough's (SP)
fertility stimulation hormone (FSH-CTP) confirms that carboxyl
terminal peptide (CTP) modification can extend the therapeutic
duration of protein drugs.
Sangamo Biosciences and Sigma-Aldrich have licensed their zinc
finger nuclease (ZFN) technology to Roche to enable the pharma
giant to develop cell lines and transgenic animals.
New Mexico-headquartered drugmaker CytoDyn has begun the good
manufacturing practice (GMP) standard production of the
developmental candidate anti-HIV monoclonal antibody Cytolin
(lymphocyte function-associated antigen-1).
Nventa Biopharmaceuticals hopes that the enhanced durability of its
new Poly IC-Poly arginine (Poly-ICR) adjuvant will help it capture
a significant share of the therapeutic and prophylactic vaccine
markets.
MDS Pharma Services has expanded its portfolio of bioanalytical
testing services with the addition of electrochemiluminescent assay
(ECLA) capability, used to test biological samples from clinical
research participants.
The Bio Affinity Company (BAC) has introduced two new products for
scientists who need to purify hard-to-separate antibodies such as
immunogloblins A and M.
The first European approval application for a vaccine delivered via
a new intradermal (ID) microinjection system developed by BD
(Becton, Dickinson & Company) has been filed by Sanofi-Pasteur,
the vaccines division of the Sanofi-Aventis...
Canadian vaccine specialist ImmunoVaccine Technologies (IVT) has
scored a multi-million dollar grant to go towards developing its
potent immune enhancement systems.
Novartis has been keen to shout about data published this week in
the Journal of the American Medical Association (JAMA)
that backs up claims that it has developed the first vaccine to
protect infants against the most common meningitis...
Pfizer, the world's largest pharma firm, has reached into its
pockets to buy CovX, a privately-held US biotech that specialises
in combining the strengths of peptides and antibodies into new
drugs.
Sanofi-Aventis recently admitted it needed to increase the number
of biotech compounds in its pipeline and now, true to its word, the
French pharma heavyweight has signed a big antibody deal with US
biotech Regeneron.
